Alnylam Pharmaceuticals, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: 2.89

Alnylam Pharmaceuticals, Inc. Current Ratio is 2.89 for the Trailing 12 Months (TTM) ending March 31, 2025, a -8.81% change year over year. Current ratio represents the short-term liquidity measurement, showing current assets' coverage of liabilities. Higher ratio implies better ability to meet short-term obligations.
  • Alnylam Pharmaceuticals, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was 3.16, a -12.60% change year over year.
  • Alnylam Pharmaceuticals, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 3.62, a -1.24% change year over year.
  • Alnylam Pharmaceuticals, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 3.67, a 9.25% change year over year.
  • Alnylam Pharmaceuticals, Inc. Current Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 3.35, a 18.62% change year over year.
Key Data
Date Current Ratio Interest Coverage Ratio Return on Capital Employed (ROCE) Return on Equity (ROE)